Page 65 - Demo456

Mover Alert
Our list of recent hires and promotions in key positions at Pharma, Life Sciences, and Healthcare companies.
team with the addition
of Lloyd Cochran as the Executive Vice President and CFO, and the promotion of Dan Wilmer to Executive Vice President and Chief Product Officer. Cochran
is an experienced CFO who has gained strategy and financial experience at large multinational brands and carried businesses through numerous acquisitions
and mergers. Wilmer’s responsibilities are increasing to include leading the enhancement of InStep’s digital, pharmacy, and select HCP offerings in order to provide reinforcements for the company’s unfolding strategic growth plans.
Merus
Andrew Joe, MD, moved from Sanofi’s immuno- oncology program to Netherlands-based biotech, Merus, as Chief Medical Officer. He will take charge of all clinical and regulatory strategy and activities while
advancing the company’s pipeline of multispecific antibodies, including the lead program, Zenocutuzumab, for neuregulin 1 fusion cancers. Joe’s track record for drug approval includes work on Merck’s Keytruda, Novartis’ Zykadia, and Roche’s Zelboarf.
Paragon Biosciences
Paragon Health Capital,
the capital markets group
of Paragon Biosciences, appointed Kerensa Jimenez as the new CEO. She will lead all financings, mergers and acquisitions (M&A) advisory services, and capital planning for Paragon Biosciences’ portfolio of innovative life sciences companies. Jimenez has a 15-year track record of successfully advising clients on M&A and financing transactions.
Prometheus Biosciences
The biopharma focused on therapies for Inflammatory Bowel Disease named Keith
W. Marshall, PhD, MBA, its Chief Financial Officer. With years of CFO experience at life sciences companies,
Dr. Marshall will lead Prometheus’ finance and investor relations functions.
ROME Therapeutics
Dennis Zaller, PhD, joins ROME as Chief Scientific Officer. The drug discovery veteran will be responsible for biology, chemistry, and preclinical development. Dr. Zaller is well known in the biopharma arena, previously serving as Executive Director, Integrative Sciences at Celgene. He also spent 25 years at Merck, where Dr. Zaller helped advance 28 molecules into the clinic, resulting in eight marketed drugs.
Spark Therapeutics
The commercial gene therapy company appoints Gallia G. Levy, MD, PhD, as Chief Medical Officer. Dr. Levy is trusted to lead the
entire product development lifecycle, including setting the global development strategy for current and future pipeline programs.
Dr. Levy joins Spark from Genentech, where she was the VP and Global Head of the Rare Blood Disorders franchise in Product Development responsible for the clinical development of Hemlibra for hemophilia A.
WuXi Vaccines
WuXi Vaccines, the vaccine contract development and manufacturing organization of WuXi Biologics and Hile Bio-Technology, named Jian Dong its Chief Executive Officer. A part of WuXi Biologics since 2014, Dong led the Wuxi site to become the first GMP biologics Drug Substance and Drug Product facilities in China certified by both the U.S. FDA and EMA. He will now help with the company’s mission to bolster the vaccine supply chain. —Kayla Walsh
September 2020 / pm360 magazine 63
shutterstock.com